KAT6A

Across TCGA pan-cancer cohorts, KAT6A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KAT6A data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KAT6A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KAT6A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where KAT6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.470	.027	6	view →
LSCC	OS	Median	All	1.000	0.937	.012	5	view →
PDAC	DFS	Tertile	III,IV	0.465	0.826	.023	4	view →
LUAD	OS	Quartile	All	0.633	0.873	.037	3	view →
HNSC	DFS	Median	III,IV	1.000	0.422	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KAT6A–CCRCC (DFS)

Open the CCRCC breakdown →